Bionexus Gene Lab Corp
(BGLC)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | |
| Sales | 127 | 212 |
| Cost of Goods | 71 | 184 |
| Gross Profit | 56 | 29 |
| Operating Expenses | 403 | 152 |
| Operating Income | -276 | 60 |
| Pre-tax Income | -276 | 60 |
| Income Tax | -29 | 33 |
| Net Income Continuous | -247 | 27 |
| Net Income | $-247 | $27 |
| EPS Basic Continuous Ops | -0.34 | 0.05 |
| EPS Diluted Continuous Ops | -0.34 | 0.05 |
| EBITDA(a) | $-222 | $101 |